(RTTNews) - Myriad Genetics, Inc. (MYGN), a genetic testing and precision medicine company, on Wednesday announced its groundbreaking study results on the Prequel Prenatal Screen with AMPLIFY technology, which enables reliable prenatal genetic testing as early as eight weeks' gestation.
This innovative technology was presented at the Society for Maternal-Fetal Medicine or SMFM Conference, where it was awarded the "Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics."
The study demonstrated that Prequel with AMPLIFY technology successfully overcomes the challenge of low fetal fraction in early gestation, providing accurate results at just eight weeks, well before the typical nine to ten weeks.
The test showed an average fetal fraction of 12.5%, with a no-call rate of less than 0.5%, offering a significant advancement in prenatal care.
This research, which will be presented in an opening plenary session on January 30, 2025, at 8:30 a.m. MT, is expected to help clinicians offer earlier and more informed decisions regarding prenatal diagnostics, such as chorionic villus sampling or CVS at 10 weeks.
The company's Prequel with AMPLIFY technology has the potential to transform prenatal care by providing early, reliable genetic insights into fetal development, allowing healthcare providers to better manage pregnancies at high risk for chromosomal abnormalities.
This innovation is a key part of Myriad's strategy to lead the future of prenatal genetic testing.
Myriad Genetics continues to build on this momentum with ongoing advancements in its genetic testing portfolio, positioning the company at the forefront of precision medicine in maternal-fetal health.
Currently, MYGN is trading at $12.37 down by 1.04%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
